Bayer’s gadavist injection gets FDA approval as MRI contrast agent
The FDA approval is based on priority review of two, multi-center, Phase III studies GEMMA-1 and GEMMA-2 carried out in 13 countries. The GEMMA principal investigator Gillian Newsteads
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.